Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle

Hepatology

Volumn 61, Issue 5, 2015, Pages 1747-1754

  Stock, Peter G ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; EMTRICITABINE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LEDIPASVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RALTEGRAVIR; RAPAMYCIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRAFT REJECTION; ANTIVIRAL THERAPY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DISEASE SEVERITY; DONOR SELECTION; DYSLIPIDEMIA; FOLLOW UP; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; LONG TERM CARE; LONG TERM EXPOSURE; MIXED INFECTION; MODEL FOR END STAGE LIVER DISEASE SCORE; MORBIDITY; MORTALITY; NUTRITIONAL STATUS; OBESITY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT INFECTION; REVIEW; SARCOPENIA; SURVIVAL RATE; VIRAL CLEARANCE; COMPLICATION; GRAFT REJECTION; HEPATITIS C, CHRONIC; POSTOPERATIVE COMPLICATIONS; RECURRENT DISEASE;

GRAFT REJECTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE;

EID: 84928204323     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27553     Document Type: Review

References (40)

1. Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008;8:355-365.
2. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007;7:2816-2820.
3. Tateo M, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009;23:1069-1076.
4. Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010;10:1268-1275.
5. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012;18:716-726.
6. Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Aguero F, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 2012;12:1866-1876.
7. Norris S, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004;10:1271-1278.
8. Vennarecci G, Ettorre GM, Antonini M, Santoro R, Perracchio L, Visco G, et al. Liver transplantation in HIV-positive patients. Transplant Proc 2007;39:1936-1938.
9. Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008;47:407-417.
10. Anadol E, Beckebaum S, Radecke K, Paul A, Zoufaly A, Bickel M, et al. Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. AIDS Res Treat 2012;2012:197501.
11. Antonini TM, Sebagh M, Roque-Afonso AM, Teicher E, Roche B, Sobesky R, et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant 2011;11:1686-1695.
12. Castells L, Rimola A, Manzardo C, Valdivieso A, Luis Montero J, Barcena R, et al.; the FIPSE LT-HIV investigators. Pegylated Interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. J Hepatol 2014 Aug 12. pii: S0168-8278(14)00538-8. doi: 10.1016/j.jhep.2014.07.034. [Epub ahead of print].
13. Terrault N, Reddy R, Poordad F, Curry M, Schiano T, Shakil O, et al.; HIVTR Investigators. Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients. Am J Transplant 2014;14:1129-1135.
14. Kemmer NM, Sherman KE. Liver transplantation trends in the HIV population. Dig Dis Sci 2011;56:3393-3398.
15. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005;5:549-557.
16. Lai JC, Verna EC, Brown RS, Jr., O'Leary JG, Trotter JF, Forman LM, et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011;54:418-424.
17. Lai JC, O'Leary JG, Trotter JF, Verna EC, Brown RS, Jr., Stravitz RT, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 2012;18:532-538.
18. + allografts. Liver Transpl 2006;12:1496-1503.
19. Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med 2010;362:2336-2337.
20. Stock P, Barin B, Murphy B, Hanto D, Diego J, Light J, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010;363:2004-2014.
21. Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009;9:1946-1952.
22. Moreno A, Barcena R, Quereda C, Casado JL, Perez-Elias MJ, Fortun J, et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS 2008;22:547-548.
23. Levitsky J, Fiel MI, Norvell JP, Wang E, Watt KD, Curry MP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012;142:1132-1139.e1.
24. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-27.
25. Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012;56:1622-1630.
26. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008;8:2426-2433.
27. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679-687.
28. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, et al., Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study, Gastroenterology. 2014 Sep 24. doi: 10.1053/j.gastro.2014.09.023 [Epub ahead of print].
29. Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis 2014;27:36-45.
30. Afdhal N, Everson G, Calleja J, McCaughan G, Symonds W, Denning J, et al., eds. Sofosbuvir and ribavirin for the treatment chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. The 49th Annual Meeting of the European Association for the Study of the Liver, April 9-13, 2014, London, UK.
31. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al., Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology. 2014 Oct 7. doi: 10.1053/j.gastro.2014.10.001 [Epub ahead of print].
32. Forns X, Prieto M, Charlton M, McHutchinson J, Symonds W, Brainard D, et al., eds. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. The 49th Annual Meeting of the European Association for the Study of the Liver, April 9-13, 2014, London, UK.
33. Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014;46:923-927.
34. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
35. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014 Jul 26 doi: 10.1016/S0140-6736(14)61036-9 [Epub ahead of print].
36. Kwo P, Mantry P, Coakley E, Te H, Vargas H, Brown R, Jr., et al., eds. Resulst of the phase 2 study of M12-999: interferon-free regimen of ABT-450/r/ABT-267+ABT-333+RIBAVIRIN in liver transplant recipients with recurrent genotype 1 infection. The 49th Annual Meeting of the European Association for the Study of the Liver, April 9-13, 2014, London, UK.
37. Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013;19:3-26.
38. Bahirwani R, Barin B, Olthoff K, Stock P, Murphy B, Rajender Reddy K, et al. Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the national institutes of health multi-site study. Liver Transpl 2013;19:619-626.
39. Chin-Hong P, Berry J, Jay N, Da Costa M, Darragh T, Roland M, et al., eds. High incidence of high-grade anal intraepithelial neoplasia in HIV-infected women and men following organ transplantation. 26th International HPV Conference, July 3-4, 2010, Montréal, Québec, Canada.
40. Nissen NN, Barin B, Stock PG. Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Curr Opin Oncol 2012;24:517-521.